Recessive Dystrophic Epidermolysis Bullosa (RDEB) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030


 Recessive dystrophic epidermolysis bullosa (RDEB) is a subgroup of hereditary blistering diseases characterized by repetitive wounding and healing with subsequent extensive scarring. Is a group of genetic disorders of the skin characterized by marked fragility and a tendency to form blisters and erosions in response to minor trauma. There are more than 12 hereditary types of EB, which are subclassified into four major forms: dominant EB simplex, recessive junctional EB, dominant dystrophic EB, and recessive dystrophic EB. Dystrophic forms of EB feature repetitive wounding and healing of the skin associated with severe scarring. A special feature of RDEB patients is a tendency to develop aggressive squamous cell carcinomas in areas of severe scarring. These cancers lead to high morbidity and mortality at a relatively early age.

The pathogenesis of RDEB remains unclear; however, two hypotheses have been extensively studied. One hypothesis is that the RDEB skin has a rudimentary or diminished number of anchoring fibrils (AF), resulting in skin fragility

According to research the incidence cases of RDEB in the USA ranges between 225 to 365 cases per million live births.

The competitive landscape of Recessive Dystrophic Epidermolysis Bullosa (RDEB) includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Recessive Dystrophic Epidermolysis Bullosa (RDEB) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Recessive Dystrophic Epidermolysis Bullosa (RDEB)  Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Recessive Dystrophic Epidermolysis Bullosa (RDEB)  – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          PTR-01 Phoenix Tissue Repair, Inc.       Phase 2

2          FCX-007           Castle Creek Biosciences, LLC. Phase 3

3          EB-101 Abeona Therapeutics, Inc          Phase 3

4          Rigosertib Sodium         Onconova Therapeutics, Inc.     Phase 1

5          Beremagene Geperpavec          Krystal Biotech, Inc.       Phase 3

6          SD-101 Scioderm, Inc.   Phase 3

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more